Invesco Ltd. Revance Therapeutics, Inc. Transaction History

Invesco Ltd.

$453 Billion
Q1 2024

A detailed history of Invesco Ltd. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 50,934 shares of RVNC stock, worth $130,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares

50,934

Previous 1,602,622 96.82%

Holding current value

$130,900

Previous $14.1 Million 98.23%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.65 - $9.31 $7.22 Million - $14.4 Million	-1,551,688 Reduced 96.82%	50,934 $250,000
Q4 2023 Feb 12, 2024	SELL	$5.81 - $11.2 $7.55 Million - $14.6 Million	-1,299,818 Reduced 44.78%	1,602,622 $14.1 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $13.2 Million - $28.9 Million	1,153,615 Added 65.97%	2,902,440 $33.3 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $37.7 Million - $57.4 Million	1,527,259 Added 689.3%	1,748,825 $44.3 Million
Q1 2023 May 12, 2023	BUY	$18.36 - $35.27 $2.85 Million - $5.47 Million	155,131 Added 233.51%	221,566 $7.14 Million

Q4 2022 Feb 13, 2023	SELL	$18.32 - $30.66 $3.19 Million - $5.34 Million	-174,255 Reduced 72.4%	66,435 $1.23 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $2.55 Million - $5.06 Million	177,802 Added 282.73%	240,690 $6.5 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $1.79 Million - $3.17 Million	-155,458 Reduced 71.2%	62,888 $869,000
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $2.21 Million - $3.63 Million	178,955 Added 454.3%	218,346 $4.26 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $33,430 - $74,775	-2,683 Reduced 6.38%	39,391 $643,000
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $138,619 - $178,570	5,377 Added 14.65%	42,074 $1.17 Million
Q2 2021 Aug 17, 2021	BUY	$26.8 - $31.84 $268,321 - $318,782	10,012 Added 37.52%	36,697 $1.09 Million
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $304,339 - $379,570	12,665 Added 90.34%	26,685 $746,000
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $513,732 - $621,921	-21,945 Reduced 61.02%	14,020 $398,000
Q3 2020 Nov 16, 2020	BUY	$23.23 - $34.3 $99,610 - $147,078	4,288 Added 13.54%	35,965 $904,000
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $399,130 - $841,024	31,677 New	31,677 $773,000
Q1 2020 May 15, 2020	SELL	$12.46 - $27.81 $147,850 - $329,993	-11,866 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $8,954 - $15,475	-768 Reduced 6.08%	11,866 $193,000
Q3 2019 Nov 14, 2019	SELL	$10.22 - $14.5 $5,028 - $7,134	-492 Reduced 3.75%	12,634 $164,000
Q2 2019 Aug 14, 2019	SELL	$10.67 - $15.49 $63,817 - $92,645	-5,981 Reduced 31.3%	13,126 $170,000
Q1 2019 May 15, 2019	BUY	$15.4 - $20.39 $294,247 - $389,591	19,107 New	19,107 $301,000

Others Institutions Holding RVNC

# of Institutions

214

Shares Held

83.4M

Call Options Held

656K

Put Options Held

424K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account